Search

Without access to treatment, can we truly innovate in rare diseases?

Interview with Giampaolo Merlini

There have been many developments on rare diseases since the EU Orphan Medicinal Products Regulation came into force in 2000. As the European Commission is evaluating its effectiveness, EHA discussed with Prof.

Read more

Clinical trials

The advance of highly innovative, increasingly personalized therapies in hematology requires novel clinical trial designs and more flexible, adaptive regulatory frameworks and improved data generation to support decision making both during and after clinical studies.

Read more

FP9 recommendations BioMed Alliance

With preparations under way for the EU’s next Framework Programme for Research and Innovation (FP9), the BioMed Alliance has called for more robust EU support for health research.

Read more

Statement

The European Hematology Association (EHA), a dedicated community of healthcare professionals, who work tirelessly "Towards prevention, cure, and quality of life for all patients with blood disorders", expresses its deep concern and sorrow over the ongoing violence and humanitarian crisis…

Read more

Clinical Practice Guidelines

EHA creates clinical practice Guidelines for diagnosis and treatment of hematologic diseases. This initiative started in 2019 with the establishment of the EHA Guidelines Committee and the definition of the EHA Methodology for Guidelines.

Read more